Deprenyl，一种具有新抗癌潜力的老药物：微型评论
Deprenyl, an old drug with new anticancer potential: Mini review
摘要：
在细胞培养物和动物进行的临床前试验中观察到单胺氧化酶（MAO）的抗癌潜力。L-丙炔苯丙胺（DEP）可引起黑色素瘤、白血病和乳腺细胞凋亡。高剂量DEP对大鼠的乳腺癌和垂体癌以及单核细胞白血病具有毒性。DEP解释了能够增加自然杀伤细胞活性、IL-2产生以及抑制肿瘤生长的免疫刺激作用。老年雌性大鼠给予DEP增加了IL-2的产生，并逆转了脾中IFN-γ产生的年龄相关性耗竭。共辅助DEP施用有助于预防/减轻癌症治疗中与周围神经病变相关的症状。它还增强了抗癌药物（如阿霉素、顺铂等）在癌细胞中的细胞毒性作用，同时保护健康细胞免受损害。DEP对垂体瘤引起的功能障碍如衰弱性激素失衡有作用;垂体产生促肾上腺皮质激素的刺激激素，这与疾病的加重有关。因此，DEP成为一种针对多种癌症类型的优秀潜在药物，并且在长期治疗的帕金森病患者中也具有低毒性。
英文摘要：
The anticancer potential of monoamine oxidase (MAO) was observed in pre-clinical assays conducted with cell cultures and animals. L-Deprenyl (DEP) causes apoptosis in melanoma, leukemia and mammary cells. High-dose DEP has shown toxicity in mammary and pituitary cancers, as well as in monoblastic leukemia, in rats. DEP accounts for immune-stimulant effect capable of increasing natural killer cell activity, IL-2 generation, as well as of inhibiting tumor growth. DEP administration in old female rats has increased IL-2 generation and inverted the age-related depletion of IFN-γ generation in the spleen. Co-adjuvant DEP administration helped preventing/mitigating symptoms associated with peripheral neuropathy in cancer treatment. It also enhanced the cytotoxic effects of antineoplastic drugs - such as doxorubicin, cisplatin, among others - in cancer cells while they protected healthy cells from being damaged. DEP presented effect against dysfunctions such as debilitating hormone imbalance triggered by pituitary gland tumor; this gland produces the stimulatory hormone of adrenocorticotropic hormone which was related to the exacerbation of this disease. Thus, DEP emerges as an excellent potential drug against several cancer types and it also presents low toxicity in Parkinson`s disease patients subjected to long treatment with it.
机构、总结、中文摘要均由AI分析而来，可能存在错误，请以论文正文为准。
